Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Alumis (NASDAQ:ALMS)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Alumis Charts.

Alumis (NASDAQ:ALMS)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Alumis Charts.

Alumis Inc News

Alumis Strengthens Leadership Team with Key Appointments
Wednesday 29 January 2025 (4 days ago) • GlobeNewswire Inc.

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
Friday 20 December 2024 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 25 November 2024 (2 months ago) • Edgar (US Regulatory)

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
Friday 15 November 2024 (3 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 14 November 2024 (3 months ago) • Edgar (US Regulatory)

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
Thursday 14 November 2024 (3 months ago) • GlobeNewswire Inc.

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
Tuesday 5 November 2024 (3 months ago) • GlobeNewswire Inc.

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
Friday 27 September 2024 (4 months ago) • GlobeNewswire Inc.

Alumis to Participate in Upcoming September Investor Conferences
Wednesday 4 September 2024 (5 months ago) • GlobeNewswire Inc.

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
Wednesday 14 August 2024 (6 months ago) • GlobeNewswire Inc.

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
Monday 29 July 2024 (6 months ago) • GlobeNewswire Inc.

More Alumis Inc News Articles

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions